Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Recruiting · NCT06440993 · Registry updated 2025-12-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | Extrahepatic Cholangiocarcinoma, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2025-12-01 | NCT06440993 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Krankenhaus Nordwest | Frankfurt | Germany | 7 |
| Medizinische Hochschule Hannover | Hanover | Germany | 42 |
| UKSH Campus Lübeck | Lübeck | Germany | 2 |
| Uniklinik RWTH Aachen | Aachen | Germany | 2 |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz | Mainz | Germany | 5 |
| Universitätsklinik Münster | Münster | Germany | 1 |
| Universitätsklinikum Bonn | Bonn | Germany | 13 |
| Universitätsklinikum Düsseldorf | Düsseldorf | Germany | 19 |
| Universitätsklinikum Köln | Cologne | Germany | 13 |
| Universitätsmedizin Göttingen | Göttingen | Germany | 11 |